Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given an average recommendation of “Moderate Buy” by the eight analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $6.8333.

A number of equities research analysts have recently commented on PYXS shares. Weiss Ratings raised shares of Pyxis Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 5th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research report on Tuesday, March 24th. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Wedbush assumed coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. Finally, Stifel Nicolaus lowered their target price on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, March 24th.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $2.23 on Friday. The firm’s fifty day simple moving average is $1.93 and its 200-day simple moving average is $1.78. Pyxis Oncology has a 12 month low of $0.97 and a 12 month high of $5.55. The stock has a market capitalization of $141.27 million, a price-to-earnings ratio of -1.70 and a beta of 1.42.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Analysts anticipate that Pyxis Oncology will post -1.23 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the company. Atle Fund Management AB acquired a new position in shares of Pyxis Oncology during the fourth quarter worth about $710,000. 683 Capital Management LLC lifted its position in Pyxis Oncology by 69.9% in the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after purchasing an additional 366,910 shares during the period. Avanza Fonder AB acquired a new stake in Pyxis Oncology in the fourth quarter valued at about $31,000. OMERS ADMINISTRATION Corp purchased a new stake in Pyxis Oncology in the 4th quarter valued at approximately $77,000. Finally, Barclays PLC boosted its holdings in Pyxis Oncology by 1,939.3% in the 4th quarter. Barclays PLC now owns 60,385 shares of the company’s stock valued at $69,000 after purchasing an additional 57,424 shares in the last quarter. 39.07% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.